534 related articles for article (PubMed ID: 27690683)
21. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation.
Blyth E; Clancy L; Simms R; Ma CK; Burgess J; Deo S; Byth K; Dubosq MC; Shaw PJ; Micklethwaite KP; Gottlieb DJ
Blood; 2013 May; 121(18):3745-58. PubMed ID: 23435462
[TBL] [Abstract][Full Text] [Related]
22. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
[TBL] [Abstract][Full Text] [Related]
23. Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options.
Fuji S; Einsele H; Kapp M
Curr Opin Infect Dis; 2017 Aug; 30(4):372-376. PubMed ID: 28505028
[TBL] [Abstract][Full Text] [Related]
24. Persistent CMV infection after allogeneic hematopoietic stem cell transplantation in a CMV-seronegative donor-to-positive recipient constellation: Development of multidrug resistance in the absence of anti-viral cellular immunity.
Herling M; Schröder L; Awerkiew S; Chakupurakal G; Holtick U; Kaiser R; Pfister H; Scheid C; Di Cristanziano V
J Clin Virol; 2016 Jan; 74():57-60. PubMed ID: 26672492
[TBL] [Abstract][Full Text] [Related]
25. New Developments in the Management of Cytomegalovirus Infection After Transplantation.
Meesing A; Razonable RR
Drugs; 2018 Jul; 78(11):1085-1103. PubMed ID: 29961185
[TBL] [Abstract][Full Text] [Related]
26. Assessment of a cytomegalovirus serology dual-testing strategy in hematopoietic stem cell transplant recipients.
Perry DA; Hakki M
Transpl Infect Dis; 2016 Oct; 18(5):809-814. PubMed ID: 27502917
[TBL] [Abstract][Full Text] [Related]
27. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
[TBL] [Abstract][Full Text] [Related]
28. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
Fleming T; Dunne J; Crowley B
J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
[TBL] [Abstract][Full Text] [Related]
29. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT
Lancet Infect Dis; 2012 Apr; 12(4):290-9. PubMed ID: 22237175
[TBL] [Abstract][Full Text] [Related]
30. Optimizing the treatment of cytomegalovirus infection in allo-HSCT recipients.
Sun YQ; Ma R; Huang XJ
Expert Rev Clin Immunol; 2023 Feb; 19(2):227-235. PubMed ID: 36541485
[TBL] [Abstract][Full Text] [Related]
31. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
[TBL] [Abstract][Full Text] [Related]
32. An update on the treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
Maffini E; Busca A; Costa C; Giaccone L; Cerrano M; Curtoni A; Cavallo R; Bruno B
Expert Rev Hematol; 2019 Nov; 12(11):937-945. PubMed ID: 31423858
[No Abstract] [Full Text] [Related]
33. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies.
Girmenia C; Lazzarotto T; Bonifazi F; Patriarca F; Irrera G; Ciceri F; Aversa F; Citterio F; Cillo U; Cozzi E; Gringeri E; Baldanti F; Cavallo R; Clerici P; Barosi G; Grossi P
Clin Transplant; 2019 Oct; 33(10):e13666. PubMed ID: 31310687
[TBL] [Abstract][Full Text] [Related]
34. Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management.
Khawaja F; Batista MV; El Haddad L; Chemaly RF
Curr Opin Infect Dis; 2019 Dec; 32(6):565-574. PubMed ID: 31567572
[TBL] [Abstract][Full Text] [Related]
35. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.
Peggs KS; Verfuerth S; Pizzey A; Khan N; Guiver M; Moss PA; Mackinnon S
Lancet; 2003 Oct; 362(9393):1375-7. PubMed ID: 14585640
[TBL] [Abstract][Full Text] [Related]
36. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.
Boeckh M; Nichols WG; Papanicolaou G; Rubin R; Wingard JR; Zaia J
Biol Blood Marrow Transplant; 2003 Sep; 9(9):543-58. PubMed ID: 14506657
[TBL] [Abstract][Full Text] [Related]
37. Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.
Van Craenenbroeck AH; Smits EL; Anguille S; Van de Velde A; Stein B; Braeckman T; Van Camp K; Nijs G; Ieven M; Goossens H; Berneman ZN; Van Tendeloo VF; Verpooten GA; Van Damme P; Cools N
Transplantation; 2015 Jan; 99(1):120-7. PubMed ID: 25050468
[TBL] [Abstract][Full Text] [Related]
38. Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation.
Ke P; Bao X; Zhou J; Li X; Zhuang J; He X; Wu D; Zhang X; Ma X
Hematology; 2020 Dec; 25(1):43-47. PubMed ID: 31906810
[No Abstract] [Full Text] [Related]
39. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
Foolad F; Aitken SL; Chemaly RF
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.
Sellar RS; Peggs KS
Expert Opin Biol Ther; 2014 Aug; 14(8):1121-6. PubMed ID: 24762099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
